Company Description
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States.
It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.
The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017.
Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Gregory Gorgas |
Contact Details
Address: 505 Lomas Santa Fe, Suite 160 Solana Beach, California 92075 United States | |
| Phone | 858 925 7049 |
| Website | artelobio.com |
Stock Details
| Ticker Symbol | ARTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001621221 |
| CUSIP Number | 04301G201 |
| ISIN Number | US04301G5080 |
| Employer ID | 33-1220924 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory D. Gorgas M.B.A. | President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director |
| Dr. Andrew Yates Ph.D. | Senior Vice President and Chief Scientific Officer |
| Jason H. Baybutt | Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 8, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 8, 2024 | ARS | Filing |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Jun 17, 2024 | 25-NSE | Filing |
| May 13, 2024 | 10-Q | Quarterly Report |
| Mar 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 25, 2024 | 10-K | Annual Report |